As oncology research advances, the tumor microenvironment (TME) remains a critical area of study, with its complex interplay of cancer cells, immune cells, and metabolites presenting both challenges and opportunities for therapeutic development. On September 1, 2026, at 10:00 AM EDT, Creative Biolabs will host an exclusive webinar titled "Modeling T Cell Dysfunction in Tumor Microenvironments," featuring Dr. Greg M. Delgoffe, Professor of Immunology at the University of Pittsburgh and Director of the Tumor Microenvironment Center at the UPMC Hillman Cancer Center.
The TME is a dynamic ecosystem where tumors create metabolic stress through nutrient depletion and accumulation of immunosuppressive byproducts. These conditions impair T cell function, leading to exhaustion and immune evasion, which ultimately reduces the efficacy of cancer immunotherapies. Traditional models often fail to capture these nuanced interactions, but advanced preclinical testing services and robust in vivo and in vitro models can better replicate these metabolic stress conditions, providing researchers with tools to investigate immune suppression and therapeutic responses under physiologically relevant conditions.
The webinar will focus on how tumor metabolic environments contribute to immune suppression and T cell exhaustion, strategies for modeling TME conditions in preclinical research, the mechanisms underlying T cell exhaustion influenced by nutrient depletion, and how immunometabolism insights can guide therapeutic strategies to enhance cancer immunotherapy. This event is particularly relevant for cancer immunology researchers, pharmaceutical and biotechnology professionals, and R&D teams dedicated to oncology drug discovery.
Dr. Delgoffe's work is instrumental in understanding the intersection of metabolism and immunity within tumors. His presentation will offer valuable insights into how researchers can model these conditions to better predict therapeutic outcomes. According to a senior scientific director at Creative Biolabs, "Understanding how metabolic conditions within tumors influence immune-cell behavior is increasingly important in immuno-oncology. Dr. Delgoffe's work provides an important perspective on how researchers can model these conditions and investigate target discovery and validation."
The implications of this webinar are significant for the field of immuno-oncology. By highlighting advanced modeling techniques, the session aims to equip researchers with the knowledge to overcome limitations of traditional models and accelerate the development of more effective cancer treatments. The ability to accurately replicate TME conditions in preclinical settings could lead to better identification of biomarkers and more precise evaluation of combination therapies, ultimately improving patient outcomes.
Creative Biolabs, a biotechnology service provider supporting immuno-oncology research and preclinical drug development, offers capabilities including antibody discovery and engineering, tumor microenvironment research, immunological assays, and customized preclinical research solutions. This webinar underscores the company's commitment to advancing research in this critical area.
For more details and to register for the webinar, interested parties can visit the official registration page.
